Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -19.56
- Piotroski Score 5.00
- Grade Buy
- Symbol (DCTH)
- Company Delcath Systems, Inc.
- Price $8.49
- Changes Percentage (-0.35%)
- Change -$0.03
- Day Low $8.37
- Day High $8.72
- Year High $11.75
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/10/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $22.00
- Low Stock Price Target $22.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.62
- Trailing P/E Ratio -2.5
- Forward P/E Ratio -2.5
- P/E Growth -2.5
- Net Income $-47,678,000
Income Statement
Quarterly
Annual
Latest News of DCTH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Delcath Systems, Inc.'s (NASDAQ:DCTH) largest shareholders are individual investors with 54% ownership, institutions own 19%
Individual investors hold the highest stake in Delcath Systems, with institutions owning 19%. Hedge funds, including Rosalind Advisors, influence the company. Insiders also own shares, indicating alig...
By Yahoo! Finance | 2 months ago -
Investors in Delcath Systems (NASDAQ:DCTH) have unfortunately lost 90% over the last five years
Delcath Systems, Inc. (NASDAQ:DCTH) has seen a 75% rise in the last quarter, but long-term holders have suffered a 90% decline over five years....
By Yahoo! Finance | 3 months ago
